NCT00367913已完成4 期
Treatment of Pulmonary Disease Caused by MAIS, M.Xenopi or M.Malmoense: A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With M.Vaccae
British Thoracic Society2 个研究点 分布在 1 个国家目标入组 400 人开始时间: 1995年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 400
- 试验地点
- 2
- 主要终点
- Unwanted effects of therapy
研究概览
简要总结
To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active in vitro against these species of mycobacteria. The primary aim of this study was to compare these to agents as supplements to rifampicin and ethambutol. A secondary aim was to assess the vale of immunotherapy with M.vaccae.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with pulmonary disease due to M.avium intracellulare, M.malmoense or M.xenopi. Aged 16 or over. With clinical and/or radiological evidence of active infection and producing sputum positive on culture on at least 2 occasions.
排除标准
- •Pregnant women and women of childbearing age not taking adequate contraceptive precautions.
- •Patients who have sputum currently positive on culture for M.tuberculosis or M.bovis.
- •Patients who have AIDS or who are known to be HIV positive
结局指标
主要结局
Unwanted effects of therapy
Death rates
Cure rates
Relapse rates
次要结局
- Benefit or not of immunotherapy with M.vaccae
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Optimization of Mycoplasm Pneumonia Antibiotic TherapyMycoplasma PneumoniaNCT01259141Capital Medical University208
已完成
1 期
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex InfectionMycobacterium Avium-Intracellulare InfectionNCT00111397National Institute of Allergy and Infectious Diseases (NIAID)2
招募中
2 期
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary InfectionLung DiseasesXenopi MycobacteriumNCT06585020Centre Hospitalier Universitaire, Amiens190
招募中
不适用
Development of Drugs for Mitochomdrial Diseases Using Patient's Skin FibroblastsMitochondrial diseasesJPRN-UMIN000014874ABE Takaaki Tohoku Univerisity Hospital50
Unknown
2 期
An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced GastrointestinalGastrointestinal CancerImmunotherapyTargeted TherapyNCT05225844Harbin Medical University150